Evidence map›Paper›PMID 41493269›Full record

ArticleACS nano2026

Stimuli-Responsive Nanozyme Reprograms Tumor Immunometabolism and Overcomes Therapeutic Resistance in Hepatocellular Carcinoma.

Yen-Nhi Ngoc Ta, Van-Anh Thi Nguyen, Thu-Thuy Can, Meng-Cheng Hsieh, Bang Giang Thi Cao, Dehui Wan, Chian-Hui Lai, Chun-Chieh Wu, Fu-Fei Hsu, Yu-Ting Yen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yen-Nhi Ngoc TaInstitute of Biomedical Engineering, National Tsing Hua University, Hsinchu 30013, Taiwan.
Van-Anh Thi NguyenInstitute of Biomedical Engineering, National Tsing Hua University, Hsinchu 30013, Taiwan.
Thu-Thuy CanInstitute of Biomedical Engineering, National Tsing Hua University, Hsinchu 30013, Taiwan.
Meng-Cheng HsiehInstitute of Biomedical Engineering, National Tsing Hua University, Hsinchu 30013, Taiwan.
Bang Giang Thi CaoInstitute of Biomedical Engineering, National Tsing Hua University, Hsinchu 30013, Taiwan.
Dehui WanInstitute of Biomedical Engineering, National Tsing Hua University, Hsinchu 30013, Taiwan.ORCID 0000-0002-5255-1731
Chian-Hui LaiGraduate Institute of Biomedical Engineering, National Chung Hsing University, Taichung 40227, Taiwan.ORCID 0000-0002-2697-4845
Chun-Chieh WuDepartment of Pathology, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan.
Fu-Fei HsuInstitute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan.
Yu-Ting YenInstitute of Translational Medicine and New Drug Development, School of Medicine, China Medical University, Taichung 40402, Taiwan.
Shen-Nien WangCollege of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Yunching ChenInstitute of Biomedical Engineering, National Tsing Hua University, Hsinchu 30013, Taiwan.ORCID 0000-0001-6228-5169

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) exhibits profound glycolytic reprogramming that drives tumor growth, impairs apoptosis, and suppresses immune responses, leading to resistance against conventional therapies. To overcome this challenge, we developed a stimuli-responsive nanozyme composed of a pH-sensitive lipid-gelatin-protamine (LGP) nanogel encapsulating glucose oxidase (GOx). This tumor-selective nanozyme depletes intratumoral glucose under acidic conditions, inducing oxidative and endoplasmic reticulum stress, upregulating death receptors, and sensitizing HCC cells to TRAIL- and doxorubicin (DOX)-induced apoptosis. Co-delivery of GOx and DOX within the nanozyme reprograms tumor immunometabolism, enhancing immunogenic cell death and promoting the release of damage-associated molecular patterns (DAMPs). These changes stimulate dendritic cell maturation and cytotoxic CD8

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularDrug Resistance, NeoplasmGlucose OxidaseLiver NeoplasmsAnimalsApoptosisCell Line, TumorDoxorubicinHumansMiceTumor MicroenvironmentAntineoplastic AgentsDoxorubicinGlucose Oxidaseglucose oxidase (GOx)glycolysishepatocellular carcinoma (HCC)immunometabolismimmunotherapypH-responsive enzyme delivery

Identifiers

PMID41493269
PMCPMC12825357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.